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Clinical and epidemiologic studies have suggested an association between infectious
agents and chronic inflammatory disorders and cancer. Better understanding of microbial
pattern-recognition receptors and innate immune signaling pathways of the host is helping
to elucidate the connection between microbial infection and chronic disease. We propose
that a key aspect of pathogenesis is an aberrant epithelial barrier that can be instigated
by microbial toxins, environmental insults, or the genetic predisposition of the host. Loss
of epithelial integrity results in activation of resident inflammatory cells bymicrobial invaders
or endogenous ligands.When coupled with a failure of normal control mechanisms that limit
leukocyte activation, a cascade is established that induces chronic inflammation and its
consequences. Here, we outline this mechanistic framework and briefly review how
alteration of innate immune response genes in murine models can provide insights into
the potential microbial origins of diverse conditions including Crohn’s disease, psoriasis,
atherosclerosis, diabetes, and liver cancer.Introduction
Humans live in direct and continuous interaction with
a startlingly complex microbial environment. The total
number of microbes (1014) normally inhabiting our mu-
cosal surfaces exceeds by an order of magnitude the
quantity of cells (1013) in our bodies. Scattered amidst
these commensal microflora are potential pathogens—
viruses, bacteria, or parasites, intrinsically capable of
producing symptomatic infectious disease. Through evo-
lution, the mammalian innate immune system has thus
been presentedwith a formidable task. First and foremost,
the host has to mount a rapid and definitive microbicidal
response to invading pathogens whose further replication
threatens significant tissue injury or organ dysfunction, yet
simultaneously tolerate legions of benign normal flora
along with nonthreatening food, water, and airborne mi-
crobes and foreign antigens. Furthermore, the most effec-
tive defense response needs to be sufficiently lethal to
rapidly kill invading pathogens while at the same time
avoid collateral damage to the host.
Patterns of local immune activation due to temporary
loss of barrier function, pathogen invasion, or release of
endogenous mediators, followed by tissue destruction
and functional impairment characterize many chronic hu-
man disease conditions (see below). The medical conse-
quences of chronic inflammation are further compoundedby potentially permanent metabolic alterations and malig-
nant transformation, as exemplified by strong associa-
tions between chronic gastritis, hepatitis, or colitis and in-
creased risk of primary carcinoma in the corresponding
organ (Kuper et al., 2000) or the link between chronic
gingivitis and insulin resistance (Pucher and Stewart,
2004). The cellular and molecular profiles of immune acti-
vation in chronic inflammatory disorders overlap consider-
ably with those patterns observed in effective, self-limited
host responses to microbial pathogens and involve similar
initiating mechanisms. This realization has provided
steady inspiration for investigations that seek to establish
causal linkages between infectious agents and chronic
inflammatory disorders or cancer. The mechanisms pro-
viding such linkages, which are just being unraveled, are
the subject of the present review.
Only rarely have specific microbial pathogens been
identified as critical and universal causes of a particular
chronic inflammatory condition or malignancy. Rheumatic
heart disease (RHD), which remains a major public health
problem indeveloping countries, is adelayedcomplication
of untreated Streptococcus pyogenes throat infections.
RHD is the pathological consequence of molecular mim-
icry—peptide sequences in the M protein of S. pyogenes
elicit crossreactive immune responses targeting self
antigens present in myosin and tropomyosin of cardiacCell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc. 823
Figure 1. A Generalized Scheme to Ex-
plain the Origin of Chronic Inflammation
Wepropose that a key early event in chronic in-
flammation is the loss of epithelial barrier integ-
rity leading to increased exposure of resident
inflammatory cells (macrophages, mast cells,
dendritic cells) to both pathogenic and non-
pathogenic microbes. Exogenous pathogen-
associated molecular patterns (PAMPs) and
endogenous ligands are recognized by the
macrophages through pattern recognition re-
ceptors (PRRs). Engagement of the PRRs trig-
gers signaling pathways that lead to the release
of chemokines and cytokines, the recruitment
and activation of lymphocytes, and the propa-
gation of chronic inflammation. Genetic factors
can influence the system at multiple check-
points.valvular myocytes. Invasive cervical cancer, the second
most commonmalignancy inwomenworldwide, is caused
by oncogenic human papillomaviruses (HPV). HPV-medi-
atedmalignant transformation of cervical epithelial cells in-
volves interference with cell cycle regulation by the viral
oncogenes E6 and E7, inducing genetic instability and
continuous selection for alterations that advance the ma-
lignant phenotype. However, as discussed below, other
viral infections, for instance the hepatitis B and C viruses
(HBV, HCV) can lead to cancer even though the viruses
do not carry oncogenes.
A direct mechanistic link between pathogen-specific
gene products and a stereotypical altered host response
key to disease development is often missing. None-
theless, clear epidemiologic associations often play out
against this enigmatic backdrop. Infections with the bac-
teriumHelicobacter pylori, subject of the 2005 Nobel Prize
in Physiology or Medicine, can produce chronic gastritis,
peptic ulcers, and appear to be a provocative factor in
60%–90% of gastric carcinomas, yet most individuals
whose stomachs play host to H. pylori develop no clinical
symptoms. Infections with the genetically unrelated HBV
and HCV can result in chronic hepatitis, liver cirrhosis, and
collectively are believed to trigger at least 50%–70% of824 Cell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc.cases of hepatocellular carcinoma (HCC); though humans
may be lifelong asymptomatic carriers of either virus.
Epstein-Barr virus (EBV) is linked to endemic Burkitt’s
lymphoma in Central Africa and nasopharyngeal carci-
noma in Southeast Asia, but lifelong asymptomatic infec-
tion or simple mononucleosis characterize the vast major-
ity of virus-host interactions. The flatworm Schistosoma
haematobium infects the urinary tract and exists in en-
demic foci within Africa, yet a subset of patients develop
a chronic granulomatous inflammatory response to para-
site eggs and consequently are prone to development of
bladder carcinoma.
The variable clinical manifestations of chronic infec-
tions, from inconsequential to life-threatening, make the
critical contribution of host factors self evident, and in
most of the diseases mentioned above it is the host re-
sponse rather than toxins or oncogenes produced by
the pathogen which causes the pathology. Advances in
our understanding of host molecules involved in microbial
recognition and innate immune signaling are beginning
to provide pieces for a more general model of infection-
associated chronic inflammatory disease (Figure 1). At
the center of this model is the primary barrier function of
skin, broncho-epithelial and mucosal epithelial surfaces,
with compromised barrier integrity representing the first
step in the pathway to macrophage activation and estab-
lishment of chronic inflammation and its sequelae in the
underlying tissues. The functional integrity of such epithe-
lial barriers can be breached directly, indirectly, or mistak-
enly en route to inflammatory activation. Many bone fide
human pathogens elaborate toxins capable of lysing
host epithelial cells or promoting their demise through
metabolic interference or triggering of apoptosis. Re-
peated exposure to noninfectious agents in our environ-
ment can also compromise barrier function, as exem-
plified by exposure to cigarette smoke and airborne
particulates which predispose to chronic bronchitis and
lung cancers. Impaired barrier function leading to micro-
bial overgrowth on epithelial surfaces can be seen in ge-
netic conditions (e.g., cystic fibrosis), as a complication
ofmedical or surgical interventions (e.g., gastric hypochlo-
rhydria or decreased intestinal peristalsis), or in the normal
aging process (e.g., loss of mucin production). And per-
haps the most intriguing concept lies in aberrant percep-
tion of microbial threats by host epithelium in the course
of its interaction with benign normal flora. A revolution in
our understanding of mammalian innate immunity has ac-
companied the elucidation of extracellular and intracellular
pattern-recognition receptors (PRRs) or sensors (e.g.,
Toll-like receptors, or TLRs, and NOD proteins) recogniz-
ing small molecular sequences often referred to as ‘‘path-
ogen-associated molecular patterns (PAMPs)’’ and the
signaling pathways through which they initiate inflamma-
tory activation. In this review, we will highlight several re-
cent advances in understanding mechanisms that link in-
fection to chronic inflammatory disease and malignancy.
Inflammation and Its Regulation
Activation of the Inflammatory Response
One of themanifestations of the host response to infection
or injury is acute inflammation characterized by a vascular
response and recruitment of circulating leukocytes, clas-
sically defined by initial recruitment of polymorphonuclear
granulocytes followed by monocytes, which differentiate
locally intomacrophages. Often, this response is triggered
bymast cell degranulation releasing a battery of inflamma-
tory mediators, including bioactive amines (histamine,
5-HT), and activation of resident macrophages through
PRRs and intracellular sensors leading to release of proin-
flammatory cytokines, such as tumor necrosis factor
(TNF)-a. This exerts a ‘‘domino effect’’ leading to sequen-
tial release of lipid mediators, cytokines, and chemokines
that drive recruitment and activation of additional inflam-
matory cells. This system has enormous capacity for syn-
ergy and redundancy, yet several key mediators have
been identified, and blocking these mediators can in turn
inhibit or attenuate the inflammatory response. A very crit-
ical mediator appears to be TNF-a, now established as an
important therapeutic target in a range of chronic inflam-
matory diseases (Feldmann and Maini, 2003) that also
provides an important link between inflammation and can-
cer (Karin and Greten, 2005).CReceptors in Acute Inflammation
Depending on the nature of the inflammatory stimulus, the
cells and the receptors that trigger the inflammatory re-
sponse following infection or injury do vary. PRRs of the
TLR family play a critical role in detection of microbes
and viruses bymacrophages and dendritic cells (reviewed
by Akira et al., 2006 [this issue of Cell]), but recent evi-
dence suggests that members of the scavenger receptor
and C-type lectin families are also important for microbial
recognition and regulation of the host inflammatory
response (Gordon, 2002; Figure 2). The C-type lectin
Dectin-1 collaborates with TLR2 to activate macrophages
exposed to b-glucans from yeast (Gantner et al., 2003).
Importantly, a number of these receptors recognize en-
dogenous ligands, for example the scavenger receptors
SR-A and CD36 mediate phagocytosis of apoptotic cells
(AC), which is associated with downregulation of macro-
phage activation (Savill et al., 2002). These receptors are
also thought to mediate uptake of oxidized lipids, thus
providing a trigger for development of atherosclerosis
(Glass andWitztum, 2001). SR-A-deficient mice exhibit in-
creased susceptibility to infection (Suzuki et al., 1997);
however, SR-A was recently shown to negatively regulate
‘‘sterile’’ zymosan (a yeast cell wall extract)-induced in-
flammation in mice (Cotena et al., 2004), suggesting that
the role of these receptors in inflammation may be con-
text dependent. The mannose receptor (MR), another
C-type lectin, has a number of endogenous ligands and
is upregulated on so-called ‘‘alternatively’’ activated mac-
rophages; MR is also thought to have a role in pathogen
recognition and regulation of innate immunity (Chieppa
et al., 2003).
Endogenous (host-derived) ligands for TLRs have also
been identified (Figure 3). Heat-shock protein 70
(HSP70), described as a TLR4 agonist (Vabulas et al.,
2002), and chromatin component HMG-B1, which ap-
pears to activate macrophages through the receptor for
advanced glycation products (RAGE; Scaffidi et al.,
2002), are released in the context of tissue injury and ne-
crosis. This observation suggests that even in the absence
of infection, TLRs andother PRRsmayplay a role in inflam-
mation and immune homeostasis through recognition of
endogenous ligands that are presented as a result of tissue
damage. Consistent with this notion, TLR4-deficient mice
are resistant to development of diet-induced atherosclero-
sis, a chronic inflammatory disease of the vasculature
(Michelsen et al., 2004). Furthermore, polymorphisms in
the human TLR4 locus have been associated with athero-
genesis (Kiechl et al., 2002), and polymorphisms in a TLR
gene cluster encoding TRL1, TLR6, andTLR10were linked
to increased prostate cancer risk (Sun et al., 2005). In the
context of chronic infection, tissue injury, and inflamma-
tion, these different families of receptors are likely to be
coordinately engaged by multiple exogenous and endog-
enous ligands (Figures 2 and 3) giving rise to a self-propa-
gating response. Recently, it was shown that mammalian
DNA and RNA, in the form of immune complexes, act as
self-antigens for TLR9 and TLR7, respectively, inducingell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc. 825
Figure 2. Surface-Exposed and Intracel-
lular PRRs and Their Corresponding
Exogenous Ligands Involved in Activa-
tion of the Macrophage Inflammatory
Response
Color matching is used to indicate the major
signal-transduction pathways activated by
functional engagement of each PRR. The
adaptor protein Cardif has also been called
MAVS, IPS-1, or VISA.IFN-a production by predendritic cells and promoting au-
toimmune inflammation (Barrat et al., 2005).
Resolution of Inflammation
Despite its self-amplifying nature, under normal circum-
stances, the acute inflammatory response is self limiting,
and after a few days, inflammation is resolved. While the
mediators and signaling mechanisms that initiate and pro-
mote the inflammatory response have become increas-
ingly well understood (see below), relatively little is known
about those factors that mediate resolution and thereby
prevent chronic inflammatory diseases from occurring. A
number of endogenous anti-inflammatory mediators
have been identified, including the cytokines interleukin
(IL)-10 and transforming growth factor (TGF)-b, and lipid
mediators, such as lipoxins and cyclopentenone prosta-
glandins. Gene disruption studies and pharmacological
inhibition have outlined a role for these mediators in neg-
ative regulation of inflammation and inflammatory disease
(Gilroy et al., 2004). More recently, a number of anti-in-
flammatory receptors on macrophages were described
(Figure 3). Of particular interest is CD200 (Wright et al.,
2000), whose engagement by the endogenous ligand
CD200L sends a ‘‘stop signal’’ to macrophages suppress-
ing production of proinflammatory mediators (Hoek et al.,
2000). CD200L, expressed on activated immune cells,
thus provides a mechanism to dampen macrophage acti-
vation after initiation of the inflammatory response. An-
other receptor that plays an important role in the negative
regulation of inflammation is the recepteur d’origine nantis
(RON), or stem cell-derived tyrosine kinase (STK) receptor826 Cell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc.in the mouse (Wang et al., 1995). The ligand for this recep-
tor ismacrophage-stimulating protein (MSP), a serumpro-
tein generated during the coagulation cascade that may
be triggered by inflammation or tissue injury, but unlike
other mediators, MSP inhibits macrophage activation
(Morrison et al., 2004). The recognition of AC by macro-
phages and dendritic cells (DC) generates anti-inflamma-
tory signals that inhibit macrophage activation and DC
maturation (Stuart et al., 2002). Different receptors have
been implicated in AC recognition including CD36, avb5
integrin, C1q and the phosphatidylserine (PS) receptor
(Fadok et al., 2001; Savill et al., 2002), but which of them
generates anti-inflammatory signals that inhibit macro-
phage and DC activation is not clear. One such receptor
could be the Mer tyrosine kinase (TK), whose absence re-
sults in defective AC clearance, development of lupus-like
autoimmune disease and increased TNF-a production
(Cohen et al., 2002). Related to Mer TK are Axl and
Tyro3, and a compound deficiency of all three receptors
results in spontaneous hyperactivation of macrophages
and DC and systemic autoimmunity (Lu and Lemke,
2001). One possible ligand for these receptors is encoded
by growth arrest-specific (GAS) gene 6, which binds PS
presented by AC (Chen et al., 1997).
Even TLRs have the capacity of inducing expression of
anti-inflammatory mediators, such as IL-10. Recent stud-
ies reveal that the signaling pathway used by TLRs to ac-
tivate expression of pro- and anti-inflammatory cytokines
(see below) diverges at the level of the TRAF3 and TRAF6
proteins, such that TRAF3 is critical for induction of IL-10
Figure 3. Endogenously Derived Ligands
and Their Interaction with Macrophage
Receptors in Modulation of the Inflam-
matory Response
Receptor-ligand interactions promoting mac-
rophage activation are indicated by (+) while
those involved in resolution of inflammation
are noted by (). AC = apoptotic cell; IC = im-
mune complex with nucleic acid; SR = scaven-
ger receptor; TLR = Toll-like receptor; Hsp =
heat-shock protein; RON = recepteur d’origine
nantis; CD200L = CD200 ligand; HMG-B1 =
high mobility group box 1 protein (chromatin
component); RAGE = receptor for advanced
glycation products; PS = phosphotidylserine;
PSR = PS receptor; GAS6 = growth arrest spe-
cific gene 6.expression, and in its absence, expression of the TRAF6-
dependent proinflammatory cytokines IL-6 and IL-12 is
dramatically upregulated (Ha¨cker et al., 2005). The bal-
ance between the TRAF3- and TRAF6-generated signals
may therefore play an important role in controlling the in-
flammatory response and its perturbation may interfere
with the proper resolution of inflammation.
Signaling Pathways that Control
and Modulate Inflammation
The inflammatory response is characterized by coordinate
activation of various signaling pathways that regulate ex-
pression of both pro- and anti-inflammatory mediators.
Currently, most of our knowledge of signaling in inflamma-
tion and innate immunity comes form studying members
of the IL-1R/TLR (Akira et al., 2006) and TNF receptor
(TNFR; reviewed by Locksley et al. [2001]) families. Al-
though structurally different, these receptors, which unlike
most cytokine and growth factor receptors lack intrinsic
protein kinase activity or are not directly associated with
protein kinases, use similar signal-transduction mecha-
nisms. Receptor engagement results in recruitment of
adaptor proteins that posses either Toll-IL-1 receptor
(TIR) domains in the case of TLRs and IL-1R (Akira et al.,
2006) or death domains (DD) in the case of thosemembers
of the TNFR family that control cell survival (Muppidi et al.,
2004). Once recruited to oligomerized receptors these
adaptors recruit a variety of signaling proteins that belong
to the TRAF family (Baud and Karin, 2001) and various pro-
tein kinases, including IRAK1 and 4 in the case of TIR sig-
naling (Suzuki et al., 2002) and RIP kinases in the case ofCTNFR signaling (Kelliher et al., 1998). Some TNFR family
members can directly recruit TRAF proteins without assis-
tance from adaptor proteins (Muppidi et al., 2004). Invari-
ably, these molecules, upon receptor engagement, acti-
vate several effector pathways, the most important of
which include mitogen-activated protein kinases (MAPK),
especially JNK (Karin and Gallagher, 2005) and p38
MAPK (Zarubin and Han, 2005), as well as IkB kinases
(IKK) and their relatives (Ghosh and Karin, 2002). The
MAPKs lead to direct and indirect phosphorylation and
activation of various transcription factors, especially those
that belong to the bZIP family: AP-1 (Karin, 1995) and
CREB (Park et al., 2005). MAPKs also regulate gene ex-
pression through posttranscriptional mechanisms such
as mRNA turnover, mRNA transport, and translation.
The IKKs, which from a complex composed of two cata-
lytic subunits, IKKa and IKKb, and a regulatory subunit,
IKKg/NEMO, are responsible for activation of NF-kB tran-
scription factors (Ghosh and Karin, 2002) and have
emerged as central regulators of inflammatory and im-
mune responses (Bonizzi and Karin, 2004). Two IKK-
related kinases TBK1/NAK/IKK3 and IKKi were found to be
important activators of interferon response factors (IRFs;
Fitzgerald et al., 2003) that, although not similar to NF-kB,
can collaborate with it to activate important target genes
(Covert et al., 2005; Werner et al., 2005). Transcriptional
cooperation also occurs between NF-kB and members of
bZIP family (Park et al., 2005). Collectively, these protein
kinases coordinate the expression of a large number of
both proinflammatory and anti-inflammatory mediators.ell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc. 827
An important anti-inflammatory cytokine is IL-10
(Pestka et al., 2004). Although the mechanisms that con-
trol IL-10 expression are not fully understood, it was re-
cently found that a TRAF3 deficiency prevents IL-10
induction in response to TLR engagement, resulting in in-
creased production of the proinflammatory cytokines IL-6
and IL-12 (Ha¨cker et al., 2005). An IL-10 deficiency also
predisposes mice to inflammatory bowel disease (IBD)
and colorectal cancer (Kuhn et al., 1993). These outcomes
were found to be dependent on colonization of the gastro-
intestinal tract with H. hepaticus (Erdman et al., 2003),
a close relative of H. pylori which, as discussed above,
is amajor risk factor for gastric cancer in humans. Interest-
ingly, the transfer of IL-10 expressing regulatory T cells
(Treg) into H. hepaticus-infected immunodeficient mice
promoted regression of colonic adenomas (Erdman et al.,
2003), illustrating the preventive and therapeutic potential
of this anti-inflammatory cytokine. The role of IL-6, whose
expression is negatively regulated by IL-10, has yet to be
examined in the IL-10/ mouse model of colorectal can-
cer; however, it should be noted that inhibition of IL-6 sig-
naling retards development of chemically induced colitis-
associated cancer (CAC) in mice (Becker et al., 2004).
CAC development is also inhibited by knocking out the
Ikkb gene in either enterocytes or myeloid cells (Greten
et al., 2004). In the latter cell type, IKKb-driven NF-kB is re-
quired for increased production of IL-6 during early stages
of the carcinogenic process, when it serves as a growth
factor for premalignant enterocytes that give rise to CAC.
Curiously, at later stages of this malignancy, the primary
source of IL-6 appear to be Th1 cells, where its production
is negatively regulated by TGF-b (Becker et al., 2004).
IL-10 and the structurally-related type I interferons
(IFNs), as well as IL-6, IL-12, and many other cytokines,
signal via receptor associated TKs that belong to the
JAK group, whose activation results in phosphorylation
and nuclear translocation of STAT transcription factors
(O’Shea et al., 2002). Engagement of cytokine receptors
as well as TLRs can also lead to activation of phosphoino-
sitide-3-kinases (PI3K), which in turn activate other pro-
teins kinases such as AKT (Martin et al., 2003).
All of these pathways, which contribute to innate immu-
nity and inflammation, are also subject to negative regula-
tion. PI3K signaling is inhibited by the PTEN phosphatase
that belongs to the protein tyrosine phosphatase (PTP)
family; some of its other members, for instance SHIP,
SHP1/2, and CD45, are responsible for negative regula-
tion of TK signaling (Neel et al., 2003). MAPK kinase phos-
phatases (MKPs), which also belong to the PTP family,
control the duration and extent of MAPK activation as
shown during TNF-a-mediated JNK activation (Kamata
et al., 2005). Inducible suppressors of cytokine signaling
(SOCS), which function as ubiquitin ligases, are responsi-
ble for the negative feedback control of JAK-STAT signal-
ing (Alexander and Hilton, 2004). Another inducible ubiqui-
tin ligase which also possesses deubiquitination activity is
A20, which functions as a negative feedback regulator of
TLR and TNFR signaling (Boone et al., 2004). A deficiency828 Cell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc.in any one of these negative regulators can result in either
‘‘spontaneous’’ chronic inflammation, perhaps reflecting
host cell activation by PAMPs present in endogenous mi-
croflora, or an exaggerated response to true infection that
culminates in severe inflammation and damage to the
host. Similar observations were recently made in mice
that harbor a variant of IKKa, IKKaAA, that can not be ac-
tivated by upstream regulators. Although IKKaAA mice do
not develop ‘‘spontaneous’’ inflammation, they develop
an exaggerated inflammatory response when challenged
with bacteria, fungal cell wall particles, or even immune
complexes (Lawrence et al., 2005). These observations in-
dicate that whereas IKKb catalytic activity is important for
the activation of NF-kB through phosphorylation of inhib-
itor of kB (IkB) proteins (Maeda et al., 2003), IKKa is re-
quired for proper termination of NF-kB activation through
phosphorylation of its RelA (p65) and c-Rel subunits (Law-
rence et al., 2005). In both cases, phosphorylation results
in polyubiquitination of the target protein, leading to its ac-
celerated degradation via the 26S proteasome. However,
while IkBdegradation is essential for NF-kB activation and
nuclear translocation, the accelerated degradation of nu-
clear Rel proteins is important for controlling the duration
of NF-kB activation. Although all of these negative regula-
tory mechanisms affect different signaling pathways, ge-
netic studies in mice have shown that even the absence
of one negative regulator is sufficient for overdriving the
innate immune system, resulting in serious inflammatory
disorders. Undoubtedly, aberrations in such negative reg-
ulatory pathways will be found to underlie various chronic
inflammatory and degenerative disorders in humans.
Mechanisms of Pathogenesis
A Link between Innate and Adaptive Immunity
In addition to fighting infections and accelerating wound
healing, inflammation has an important role in shaping
the adaptive immune response; a prominent aspect of
this is the maturation and migration of DC from the sites
of infection, where they may pick up antigens, to second-
ary lymphoid organs, where they can prime antigen-spe-
cific immune responses. There have beenmajor advances
in understanding DC biology and function (Mellman and
Steinman, 2001). It is now clear that both proinflamma-
tory cytokines, including TNF-a, and microbial products
drive DC maturation and their migration to draining lym-
phoid tissue. Expression of different chemokines may dif-
ferentially affect the location of DCs. Importantly, inflam-
matory chemokines, whose expression depends on the
classical NF-kB pathway, usually promote the migration
of DCs to sites of inflammation, where they take up anti-
gens (Bonizzi and Karin, 2004). By contrast, organogenic
or homeostatic chemokines that are controlled by an alter-
native NF-kB signaling pathway (which depends on IKKa
homodimers instead of classical trimembered IKK com-
plexes) come into play at a later point during the immune
response and promote migration of antigen-loaded DCs
back into lymphoid organs (Bonizzi and Karin, 2004).
Crosstalk between the innate and adaptive immune
system is extensively reviewed by Pulendran and Ahmed
(2006) in this issue ofCell and will not be discussed further
here, but as outlined below, a switch from an acute but
short-lived inflammatory response driven by granulocytes
and macrophages to a delayed lymphocyte-dominated
response is classically associated with chronic inflamma-
tion. It has also been suggested that specific TLRs are re-
quired for generation of distinct immune and autoimmune
responses. Sequential engagement of the B cell receptor
and TLR9 by mammalian chromatin can lead to activation
of chromatin-reactive B cells and formation of anti-DNA
antibodies and chromatin containing immune complexes
(Leadbetter et al., 2002), a finding corroborated by the ab-
sence of such antibodies in TLR9-deficient lupus-prone
mice (Christensen et al., 2005). Future studies may be
warranted to examine whether RNA-recognizing TLRs
(3, 7, or 8) are involved in generation of ribonucleoprotein
and RNA-directed autoantibodies, as evidence exists that
viral dsRNA can aggravate lupus nephritis in a TLR3-
specific fashion (Patole et al., 2005). Beyond TLRs, the in-
nate immune response to nucleic acids can be mediated
by soluble intracellular receptors, such as the helicase
RIG-I (for RNA) and yet-to-be-identified receptors for dou-
ble-stranded DNA (Ishii et al., 2006; Yoneyama et al.,
2004). Both types of receptors signal to IKK and IKK-like
kinases via adaptor protein Cardif/MAVS/IPS-1/VISA (His-
cott et al., 2006). It has been suggested that these newly
identified pathways may also be involved in autoimmune
disease.
Autoimmunity
Chronic inflammatory diseases can encompass autoim-
mune disease such as rheumatoid arthritis (RA) and sys-
temic lupus erythematosus (SLE). Autoimmune diseases
remain one of the greatest mysteries in immunobiology.
Although genetic predisposition surely plays an important
part in the etiology of such diseases (Rioux and Abbas,
2005), exposure to infectious agents may also play an im-
portant but currently contentious role (Benoist andMathis,
2001). Environmental factors and customs, such as smok-
ing, that enhance exposure to bacteria and viruses and
their nucleic acids, also have an important effect on the
development of course of such diseases (Benoist andMa-
this, 2001; Rioux and Abbas, 2005). A thorough discussion
of the pathogenic role played by autoimmunity is beyond
the scope of this review and was recently addressed else-
where (Feldmann and Steinman, 2005; Rioux and Abbas,
2005). It is worth noting, however, that in addition to the
etiologic association of streptococcal infection with rheu-
matic fever, antigenic mimicry of microbial epitopes has
gained attention as a potential provocative factor in the
autoimmune tissue injury of chronic (postinfectious)
Lyme arthritis (Steere and Glickstein, 2004), central ner-
vous system demyelination in multiple sclerosis (Sospe-
dra and Martin, 2005), and the inflammatory joint destruc-
tion of RA (Prakken et al., 2001).
Failure of Resolution
An alternative view on the etiology of chronic inflammatory
disease is that a failure of endogenous anti-inflammatorymechanisms results in persistent inflammation that may
also lead to autoimmunity. This has been proposed in
the case of SLE, an autoimmune syndrome that is associ-
ated with presence of autoantibodies usually directed
against nucleic acids (Kotzin, 1996). Studies in mice
have established a role for the complement receptor
C1q on macrophages in development of this disease.
C1q is important for the phagocytic clearance of AC,
and in its absence, mice develop a SLE-like syndrome
(Botto et al., 1998). Mer TK null mice also exhibit SLE-like
pathology, where persistence of AC and necrotic bodies
are proposed to lead to development of an inappropriate
immune response to endogenous antigens (Cohen et al.,
2002). In DNaseII-deficient mice, failure of macrophages
to degrade apoptotic DNA upon engulfing AC was shown
to result in effective activation of IFN signaling (Kawane
et al., 2003). The phagocytosis of AC may play an impor-
tant role in the negative regulation of macrophage activa-
tion, promoting TGF-b production (Savill et al., 2003) and
direct repression of the IL-12p35 gene, independent of au-
tocrine or paracrine effects of TGF-b (Kim et al., 2004). For
all these reasons, defective clearance of AC may be criti-
cal in the etiology of chronic inflammatory disease.
What Have We Learned from Mice?
In this section, we discuss recent evidence for the involve-
ment of host defense mechanisms in development of
inflammatory diseases, such as Crohn’s disease (CD)
and psoriasis, as well as chronic diseases such as athero-
sclerosis, type II diabetes, and cancer. Many of these im-
portant insights have been derived from mouse models in
which genetic manipulation of innate immune and inflam-
matory signaling was examined for its effect on disease
development and progression.
Crohn’s Disease
CD is a chronic inflammatory bowel disease (IBD) with
strong genetic determinants. Approximately 40% of CD
cases found in Caucasians are linked to sequences vari-
ants of the NOD2 locus, homozygosity to any of which in-
creases disease risk by up to 40-fold (Hugot et al., 2001;
Ogura et al., 2001). NOD2 encodes a protein that belongs
to the NOD-LRR superfamily, whose members are
thought to be involved in pattern recognition and host de-
fense (Inohara et al., 2004). At its N terminus, NOD2 con-
tains two caspase activation and recruitment domains
(CARD), whereas its C terminus contains a series of leu-
cine-rich repeats (LRR), similar to those found in TLRs.
In the middle of the molecule lies a nucleotide binding
and oligomerization domain (NOD). Curiously, the CD-
linked NOD2 variants specify only small variations in the
NOD2 primary structure, all of which are within or next to
the LRR. Two of the variants, R702W and G908R result
in single amino acid substitutions, whereas the third,
1007fs (or 3020insC), is a frameshift mutation that deletes
the last 30 amino acids of the protein (Eckmann and Karin,
2005). Since no mutations that completely prevent ex-
pression of NOD2 or cause a large truncation have been
found and heterozygosity for any of the disease-linkedCell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc. 829
alleles only increases the risk of CD by 2- to 4-fold, it has
been argued that thesemutations are likely to result in a re-
cessive gain of function rather than a loss of function or the
creation of a dominant-negative variant (Eckmann and
Karin, 2005). Nonetheless, the effects of the CD-associ-
ated mutations on NOD2 function remain controversial.
Furthermore, mutated NOD2 alleles are neither sufficient
nor necessary for the development of CD, since they oc-
cur in healthy individuals and the majority of CD patients
do not exhibit NOD2 mutations (Economou et al., 2004).
The presence of a LRR suggested that NOD2 may be
a PRR. Indeed, transient NOD2 expression in heterolo-
gous cells confers responsiveness to muramyl dipeptide
(MDP), a component of gram-positive and -negative bac-
terial cell walls, measured through activation of an NF-kB-
dependent reporter (Inohara et al., 2004). Although direct
binding of MDP to NOD2 remains to be demonstrated,
these findings fostered the view that NOD2, a cytoplasmic
protein mostly expressed by myeloid cells, is involved in
recognition of intracellular bacteria. These findings fit the
view that in addition to well-established genetic risk fac-
tors, pathogenesis of CD is strongly influenced by poorly
defined environmental factors, the most likely of which
are enteric bacteria (Isaacs and Sartor, 2004). However,
apart from the strong association of NOD2 mutations
with CD and the observation that a subgroup of CD
patients responds to antibiotic therapy, the role of enteric
bacteria in CD development is far from established.
In an attempt to better understand the function of
NOD2, mutant mouse strains were created, including
complete knockouts that no longer express the protein
(Kobayashi et al., 2005; Pauleau and Murray, 2003), as
well as a Nod2 knockin mutant, which mimics the human
NOD21007fs mutation that deletes the last 30 amino acids
of the protein (Maeda et al., 2005a). Consistent with the
putative innate immune function of NOD2, Nod2/ mice
were found to be more susceptible to oral infection with
Listeriamonocytogenes, a bacterium that replicates within
macrophages (Kobayashi et al., 2005). These mice, how-
ever, do not exhibit increased colonic or intestinal inflam-
mation nor overproduce any of the proinflammatory cyto-
kines that characterize the human disease. Furthermore,
Nod2/mice exhibit resistance to acute systemic inflam-
mation induced by injection of LPS plus MDP (Kobayashi
et al., 2005). Susceptibility to bacterial infection has not
yet been tested in the Nod2 knockin mice, but these ani-
mals were found to display an elevated inflammatory re-
sponse upon administration of dextran sulfate salt (DSS),
an irritant that errodes the mucosal epithelial barrier and
thereby exposes lamina propria macrophages to enteric
bacteria (Maeda et al., 2005a). Increased inflammation in
Nod2 knockin mice is associated with elevated secretion
of mature IL-1b upon exposure to MDP or MDP combined
with LPS. Inhibition of IL-1b signaling by injection of IL-1
receptor antagonist (IL-1Ra) inhibited DSS-induced co-
lonic inflammation and abolished the phenotypic differ-
ences between the Nod2 knockin mice and wild-type
counterparts (Maeda et al., 2005a). Collectively, these re-830 Cell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc.sults support the view that NOD2 plays a critical role in the
regulation of IL-1b processing and secretion. It should be
noted that IL-1b is first made as a large precursor, pro-IL-
1b, that cannot be secreted by activated macrophages.
Conditions and signals that promote activation of caspase
1 can induce pro-IL-1b processing and IL-1b secretion
(Martinon and Tschopp, 2004). Hence, the CD-associated
mutations may increase disease risk by increasing the
capability of NOD2 to promote caspase 1 activation and
thereby enhance pro-IL-1b processing and IL-1b secre-
tion. This hypothesis is supported by biochemical experi-
ments that suggest that NOD2 is an important mediator of
pro-IL-1b processing in response to MDP and other stim-
uli (Maeda et al., 2005a). Furthermore, the resistance of
Nod2/ mice to systemic inflammation caused by MDP
plus LPS could well be due to defective IL-1b release. Cu-
riously, increased secretion of mature IL-1b caused by
mutations in the NALP3 gene, which encodes another
member of the NOD-LRR family involved in caspase 1 ac-
tivation and pro-IL-1b processing, were linked to a group
of related autoinflammatory diseases: Muckle-Wells syn-
drome (MWS), familial cold urticaria (FCU), and chronic in-
fantile neurological cutaneous and articular syndrome
(CINCA; Martinon and Tschopp, 2004). All of these closely
related diseases, whose variable signs include sensori-
neural deafness, rashes, systemic amyloidoses, nonspe-
cific limb pain, skin lesions, joint inflammation, conjuncti-
vitis, chills, and cold-induced fever, are likely to be
caused by elevated IL-1b secretion and can therefore be
treated by administration IL-1 receptor antagonist (Haw-
kins et al., 2003).
Psoriasis
Psoriasis is a chronic inflammatory disease of the skin and
joints that, just like CD andRA, involves increased produc-
tion of proinflammatory cytokines, such as TNF-a. Corre-
spondingly, all three of these diseases are responsive to
anti-TNF therapy (Feldmann and Maini, 2003). Curiously,
NOD2 mutations, different from those associated with
CD, were found to be associated with increased risk for
psoriatic arthritis (Rahman et al., 2003). This suggests
that like CD, psoriasis may also be a disease of the innate
immune system. However, apart from NOD2, several
other psoriasis susceptibility loci have been identified,
and their molecular nature and relationship to innate im-
munity remain to be elucidated (Nickoloff and Nestle,
2004).
New insights to the pathogenesis of psoriasis have been
provided by a recently developed mouse model (Zenz
et al., 2005). Following the observation that expression
of the AP-1 subunit JunB is downregulated in psoriatic le-
sions relative to normal skin, Zenz et al. (2005) generated
conditional knockoutmicewhere both the JunB and c-Jun
loci are inducibly deleted in the epidermis upon tamoxifen-
inducedCre recombinase expression.Within 8–10 days of
tamoxifen administration, affected mice, in which both
JunB and c-Jun were deleted, developed skin lesions
that were identical in appearance to psoriatic plaques of
human patients. Appearance of psoriatic lesions was
associated with appearance in 100% of the double-
knockoutmice of joint inflammation, similar to psoriatic ar-
thritis, which appears in 5%–40% of psoriasis patients.
Appearance of skin and joint lesions was associated
with upregulation of proinflammatory cytokines and che-
mokines, including TNF-a and IL-1b. Importantly, deletion
of the type I TNF-a receptor (TNFR1) resulted in milder
skin lesions and almost complete inhibition of joint inflam-
mation. Inactivation of the Rag2 locus, which prevents de-
velopment of T and B lymphocytes, which are believed to
be important contributors to the maintenance of psoriasis
and RA (Feldmann andMaini, 2003), suppressed develop-
ment of psoriatic lesions less than deletion of TNFR1 but
still attenuated the development of subsequent arthritis
(Zenz et al., 2005). These results suggest that psoriasis,
at least in epidermal-specific JunB/c-Jun-deficient mice,
is partially associated with initial activation of TNFa-pro-
ducing myeloid cells, which contribute to some of the
skin pathology, and that activation of these cells results
in longer lasting activation of lymphoid cells, which medi-
ate the arthritic lesions.
The key question, however, is what causes the initial
and deregulated activation of myeloid cells in the skin of
epidermally deleted JunB/c-Jun knockout mice. Although
the full mechanism remains to be determined, Zenz et al.
offer a few important clues. First, the development of the
disease is attenuated by application of a broad-spectrum
antibiotic, suggesting the involvement of bacteria, most
likely commensals that live on mouse skin. Second, one
of the first detectable changes in gene expression by epi-
dermal keratinocytes following inducible JunB/c-Jun de-
letion is upregulation of S100 proteins (S100A8 and
S100A9), which have been shown to serve as chemotactic
factors for neutrophils (Rioux and Abbas, 2005). Rapid up-
regulation of S100A8 and S100A9 was also seen upon de-
letion of JunB and c-Jun in cultured keratinocytes, sug-
gesting a close link between the two (Zenz et al., 2005).
As the two Jun proteins are important regulators of kerati-
nocyte proliferation (Zenz et al., 2003), it is possible that
their absence may result in increased exposure to com-
mensal bacteria due to accelerated loss of barrier func-
tion. Together with the upregulation of S100 proteins
and other yet-to-be identified factors, this results in an ex-
acerbated inflammatory response that fails to resolve and
eventually leads to activation of lymphocytes that may
propagate psoriatic arthritis through autoimmune mecha-
nisms. While it will be important to validate this hypothesis
in human subjects, it should be recognized that a patient
suffering frompsoriasismay be far removed from the initial
episode that exposed its inflammatory cells to skin-born
bacteria and therefore unlike the inducible JunB/c-Jun
knockout mice may no longer be responsive to antibiotic
therapy.
Atherosclerosis and Type II Diabetes
Atherosclerosis and type II diabetes are very common and
chronic metabolic diseases that although not strongly as-
sociated with microbial or viral exposure are dependent
on activation of macrophages. The role of activated mac-Crophages in formation of atherosclerotic plaques is well
established and extensively reviewed (Glass andWitztum,
2001). Most likely, the major cause of persistent macro-
phage recruitment and activation within developing ath-
erosclerotic plaques are oxidized forms of LDL taken up
by scavenger receptors (Febbraio et al., 2000). While the
signaling mechanisms used by scavenger receptors re-
main to be identified, they likely function as PRRs, whose
occupancy leads to macrophage activation and subse-
quent production of inflammatory mediators, including
growth factors that cause hyperproliferation of smooth
muscle and endothelial cells in blood vessels, culminating
in formation of atherosclerotic plaques (Glass and Witz-
tum, 2001).
Type II diabetes is a metabolic disease caused by de-
creased sensitivity to insulin, thus creating an increased
demand for insulin production by pancreatic b cells, which
are eventually destroyed through a mechanism that may
depend on persistent endoplasmic reticulum (ER) stress
(Ozcan et al., 2004). An important clue for the role of
inflammation in the pathogenesis of type II diabetes was
provided by the finding that TNF-a leads to insulin resis-
tance through activation of signaling pathways, such as
the JNK MAPK cascade (Hirosumi et al., 2002), that de-
crease the ability of insulin receptors to activate effector
pathways (Hotamisligil et al., 1996). For many years, the
source of TNF-a and other inflammatory cytokines capa-
ble of inducing insulin resistancewas thought to be the ad-
ipocyte. However, recent studies based on selective inac-
tivation of the classical NF-kB pathway in myeloid cells
suggest that migratory macrophages may be the major
source of proinflammatory cytokines in obesity-induced
insulin resistance (Arkan et al., 2005). How obesity leads
to activation of macrophages is a matter of conjecture,
but it is tempting to speculate that it is the uptake of certain
circulating lipids or lipoproteins through scavenger recep-
tors or engagement of other types of PRRs that may be in-
volved. Alternatively, excessive lipid accumulation and
metabolismmay result in necrotic cell death of adipocytes
or hepatocytes, for instance, through elevated production
of reactive oxygen species (ROS). As discussed above,
necrotic cells release a variety of mediators that can
lead to macrophage recruitment and activation through
PRRs. Thus, although not a direct response to microbial
infection or exposure, both atherosclerosis and type II di-
abetes can be viewed as diseases caused by excessive
and recurrent tissue injury that exposes inflammatory cells
to endogenous PRR ligands (Figure 2). This hypothesis
can be tested by examining the effect of targeted disrup-
tions of key elements of innate immune signaling such as
the MyD88 adaptor protein.
Cancer
The relationships and mechanisms through which infec-
tion and inflammation increase cancer risk and promote
tumor development were recently reviewed (Karin and
Greten, 2005). It is well established that chronic infections
with hepatitis B and C viruses (HBV, HCV) represent major
risk factors for development of hepatocellular carcinomaell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc. 831
(HCC), while chronic H. pylori infection is the major risk
factor for gastric cancer (Kuper et al., 2000). It was pro-
posed that in both cases and others the infectious agent
leads to activation of NF-kB in myeloid cells (and eventu-
ally in lymphoid cells), resulting in production of growth
and survival factors that stimulate tumor progression
and development (Karin and Greten, 2005). Interestingly,
HCV was recently found to encode a nonstructural protein
(NS5A) that actually inhibits the activation of NF-kB by
TNF-a and, as a result, potentiates TNF-a-induced JNK
activation (Park et al., 2003). Another HCV protein, NS3/
4A, is a protease that cleaves TRIF and Cardif, thereby
preventing IKK activation and induction of antiviral innate
immunity (Meylan et al., 2005). Importantly, inhibition of
NF-kB activation in hepatocytes, the cells that are infected
by HCV, was found to increase their susceptibility to car-
cinogen-induced death (Maeda et al., 2005b) However,
hepatocyte death also triggers through inflammation-
propagated mechanisms the compensatory proliferation
of surviving hepatocytes. The latter depends both on
JNK activation within hepatocytes (Maeda et al., 2005b)
and on production of proinflammatory cytokines, such
as TNF-a and IL-6, by inflammatory cells (Fausto, 2000).
It thus seems that HBV and HCV infections, for instance,
stimulate the development of HCC through both nonspe-
cific injury caused by the cytolysis of virally-infected hepa-
tocytes and through expression of specific proteins that
alter the balance between TNF-a-triggered survival and
death pathways. The necrotic death of hepatocytes is
likely to cause acute activation of liver myeloid cells
(Kupffer cells), thereby stimulating the production of
growth factors that trigger the compensatory proliferation
of surviving hepatocytes, which otherwise spend most of
their life in the Go phase of the cell cycle. Compensatory
hepatocyte proliferation results in propagation of onco-
genic mutations, induced by exposure to exogenous or
endogenous carcinogens, leading to clonal expansion of
transformed cells that eventually give rise to HCC. As in
other inflammatory diseases, chronic viral hepatitis even-
tually results in persistent activation of inflammation-
maintaining T cells (Chisari and Ferrari, 1995). Such T cells
can induce the development of HCC when transferred to
naive mice.
Thus, even in cancer, especially HCC, one can invoke
the general model of repeated tissue injury associated
with chronic exposure to a pathogen, resulting in acute
and then sustained chronic inflammation as the major
mechanism underlying the development of a long-lasting
chronic disease. Recent work on amousemodel of gastric
cancer suggests that repeated tissue injury caused by
bacterial infections (in this case caused by a relative of
H. pylori—H. felis) is associated with an aberrant regener-
ative response that may account for this type of cancer as
well (Houghton et al., 2004). Given the well-established tu-
mor-promoting function of chronic inflammation (Karin
and Greten, 2005) and the requirement of tumor promo-
tion for enhancing cancer development after carcinogen
exposure, it is not too farfetched to suggest that chronic832 Cell 124, 823–835, February 24, 2006 ª2006 Elsevier Inc.airway inflammation caused by repeated exposure to
irritants found in tobacco smoke, which enhance expo-
sure to airborne microbes and viruses, plays an important
tumor-promoting function in the development of lung can-
cer as well.
Summary
Nearly one and half centuries ago, Rudolf Virchow ex-
tended the conceptual framework of the cell theory to pro-
vide the cornerstones of modern clinical pathology: dis-
eases of organs reflected abnormal physiology of cells,
and propagations of physiologically altered cells were
the root of chronic inflammation and cancer. Insistent on
the universality of his model, Virchow vigorously rejected
the germ theory of disease proposed by his contempo-
raries Robert Koch and Louis Pasteur. In the era ofmodern
molecular medicine, clarification of the intricacy of normal
innate immune system function and its specific vulnerabil-
ities suggest that integrated ‘‘germ-cell’’ theories are re-
quired to adequately understand many chronic disease
conditions and cancers with an eye toward improved ther-
apy and cure. Indeed, the 2005 Nobel Prize in Physiology
or Medicine awarded to Barry J. Marshall and J. Robin
Warren acknowledged this point. As cited in the press re-
lease of the Nobel Assembly: ‘‘Many diseases in humans
such as Crohn’s disease, ulcerative colitis, rheumatoid ar-
thritis, and atherosclerosis are due to chronic inflamma-
tion. The discovery that one of themost common diseases
of mankind, peptic ulcer disease, has a microbial cause
has stimulated the search for microbes as possible
causes of other chronic inflammatory conditions. Even
though no definite answers are at hand, recent data clearly
suggest that a dysfunction in the recognition of microbial
products by the human immune system can result in dis-
ease development. The discovery of Helicobacter pylori
has led to an increased understanding of the connection
between chronic infection, inflammation, and cancer.’’
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